Predictive Value of Sp1/Sp3/FLIP Signature for Prostate Cancer Recurrence

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Bedolla, Roble G ^a   Gong, Jingjing ^a   Prihoda, Thomas J ^a   Yeh, I Tien ^a,d   Thompson, Ian M ^a,b   Ghosh, Rita ^a,b   Kumar, Addanki P ^a,b,c  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d VIRGINIA HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FLICE INHIBITORY PROTEIN; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; ENZYME ACTIVITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGED; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RECURRENCE; ROC CURVE; SP1 TRANSCRIPTION FACTOR; SP3 TRANSCRIPTION FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84866397957     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044917     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Manne U, Srivastava RG, Srivastava S, (2005) Recent advances in biomarkers for cancer diagnosis and treatment. Drug Discov Today 10: 965-976.
3. Grizzle WE, Semmes OJ, Basler J, Izbicka E, Feng Z, et al. (2004) The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology. Urol Oncol 22: 337-343.
4. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, et al. (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294: 66-70.
5. Salagierski M, Schalken JA, (2012) Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol 187: 795-801.
6. Kristiansen G, (2012) Diagnostic and prognostic molecular biomarkers for prostate cancer. Histopathology 60: 125-141.
7. Lopergolo A, Zaffaroni N, (2009) Biomolecular markers of outcome prediction in prostate cancer. Cancer 115: 3058-3067.
8. Lughezzani G, Briganti A, Karakiewicz PI, Kattan MW, Montorsi F, et al. (2010) Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol 58: 687-700.
9. Fromont G, Rozet F, Cathelineau X, Ouzzane A, Doucet L,et al. (2012; doi: 10.1002/pros.22485) BCAR1 expression improves prediction of biochemical reccurence after radical prostatectomy. Prostate.
10. Garcia GE, Wisniewski HG, Lucia MS, Arevalo N, Slaga TJ, et al. (2006) 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6. Clin Cancer Res 12: 980-988.
11. Kumar AP, Bhaskaran S, Ganapathy M, Crosby K, Davis MD, et al. (2007) Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res 13: 2784-2794.
12. Ghosh R, Garcia GE, Crosby K, Inoue H, Thompson IM, et al. (2007) Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. Neoplasia 9: 893-899.
13. Ganapathy M, Ghosh R, Jianping X, Zhang X, Bedolla R, et al. (2009) Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model. Clin Cancer Res 15: 1601-1611.
14. Hosmer DW, Lemeshow S (2000) Applied Logistic Regression. 2nd ed. New York, NY: John Wiley & Sons, Inc.
15. Nielsen ME, Partin AW, (2007) The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer. Rev Urol 9: 57-62.
16. Herman CM, Kattan MW, Ohori M, Scardino PT, Wheeler TM, (2001) Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol 25: 657-660.
17. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, et al. (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64: 5232-5236.
18. Yap TA, Zivi A, Omlin A, de Bono JS, (2011) The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 8: 597-610.
19. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520.
20. Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, et al. (2012) Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 61: 549-559.
21. Shariat SF, Scherr DS, Gupta A, Bianco FJ Jr, Karakiewicz PI, et al. (2011) Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Arch Esp Urol 64: 681-694.
22. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, et al (2012) Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104: 125-132.
23. Payton S, (2012) Prostate cancer: PSA screening-more data, more debate. Nat Rev Urol 9: 59.
24. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, et al. (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388: 190-195.
25. Golks A, Brenner D, Fritsch C, Krammer PH, Lavrik IN, (2005) c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem 280: 14507-14513.
26. Rippo MR, Moretti S, Vescovi S, Tomasetti M, Orecchia S, et al. (2004) FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 23: 7753-7760.
27. Mathas S, Lietz A, Anagnostopoulos I, Hummel F, Wiesner B, et al. (2004) c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 199: 1041-1052.
28. Rogers KM, Thomas M, Galligan L, Wilson TR, Allen WL, et al. (2007) Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. Mol Cancer Ther 6: 1544-1551.
29. Ullenhag GJ, Mukherjee A, Watson NF, Al-Attar AH, Scholefield JH, et al. (2007) Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res 13: 5070-5075.
30. Korkolopoulou P, Saetta AA, Levidou G, Gigelou F, Lazaris A, et al. (2007) c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Histopathology 51: 150-156.
31. Bullani RR, Huard B, Viard-Leveugle I, Byers HR, Irmler M, et al. (2001) Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol 117: 360-364.
32. Thomas RK, Kallenborn A, Wickenhauser C, Schultze JL, Draube A, et al. (2002) Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am J Pathol 160: 1521-1528.
33. Benesch M, Platzbecker U, Ward J, Deeg HJ, Leisenring W, (2003) Expression of FLIP(Long) and FLIP(Short) in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia 17: 2460-2466.
34. Korkolopoulou P, Goudopoulou A, Voutsinas G, Thomas-Tsagli E, Kapralos P, et al. (2004) c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology 63: 1198-1204.
35. Lee SH, Kim HS, Kim SY, Lee YS, Park WS, et al. (2003) Increased expression of FLIP, an inhibitor of Fas-mediated apoptosis, in stomach cancer. APMIS 111: 309-314.
36. Essafi-Benkhadir K, Grosso S, Puissant A, Robert G, Essafi M, et al. (2009) Dual role of Sp3 transcription factor as an inducer of apoptosis and a marker of tumour aggressiveness. PLoS One 4: e4478.
37. Kennett SB, Udvadia AJ, Horowitz JM, (1997) Sp3 encodes multiple proteins that differ in their capacity to stimulate or repress transcription. Nucleic Acids Res 25: 3110-3117.
38. Li L, Davie JR, (2010) The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat 192: 275-283.
39. Li R, Wheeler T, Dai H, Frolov A, Thompson T, et al. (2004) High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol 28: 928-934.